Consensus 2seventy bio, Inc.

Equities

TSVT

US9013841070

Delayed Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
5.35 USD -0.56% Intraday chart for 2seventy bio, Inc. +7.21% +25.29%

Evolution of the average Target Price on 2seventy bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1f2e1d5089412627e729c88d.dyeYqjNUribzoOI3NZs0n85AqugWGc-YmnwzEBiERQo.I1L14FUt90eR6JB0V_9Z8YYBh71Ccqfxrw8EZk7gLycFRs_MUALZFLrlow~d210e3e44b1e9752414b2c5728944861
Leerink Upgrades 2seventy bio to Outperform From Market Perform, Raises Price Target to $18 From $5 MT
TD Cowen Downgrades 2seventy bio to Market Perform From Outperform MT
Wedbush Raises 2seventy bio's PT to $5 From $2 After Announced Sale of Research, Development Projects to Regeneron, Keeps Neutral Rating MT
Wedbush Downgrades 2seventy bio to Neutral From Outperform, Does Not See Clear Catalyst for Shares Near Term; Lowers PT to $2 From $4 MT
Wedbush Adjusts 2seventy bio Price Target to $4 From $7, Maintains Outperform Rating MT
Wedbush Adjusts 2seventy bio Price Target to $7 From $11, Maintains Outperform Rating MT
Citigroup Initiates 2seventy bio at Buy Rating With $13 Price Target MT
Guggenheim Downgrades 2seventy bio to Neutral From Buy MT
Goldman Sachs Downgrades 2seventy bio to Neutral From Buy With $5 Price Target MT
Wedbush Lowers 2seventy bio's Price Target to $11 From $22, Keeps Outperform Rating MT
Guggenheim Adjusts Price Target on 2seventy bio to $26 From $27, Maintains Buy Rating MT
Goldman Sachs Cuts Price Target on 2seventy bio to $24 From $27, Maintains Buy Rating MT
Morgan Stanley Downgrades 2seventy bio to Equalweight From Overweight, Adjusts Price Target to $13 From $25 MT
Wedbush Lowers 2seventy bio's PT to $22 From $26, Removes DARIC33 From Valuation, Adjusts ABECMA Sales Ramp; Keeps Outperform Rating MT
Morgan Stanley Adjusts Price Target on 2seventy bio to $25 From $28, Maintains Overweight Rating MT
Wedbush Raises 2seventy bio's Price Target to $26 From $24, Adjusts ABECMA Profit/Loss Assumptions; Keeps Outperform Rating MT
Wedbush Raises 2seventy bio's PT to $24 From $21, Updates Model to Include Adjustments to ABECMA Sales Ramp; Keeps Outperform Rating MT
Wedbush Lowers 2seventy bio's Price Target to $21 From $28, Keeps Outperform Rating MT
Wedbush Raises 2seventy bio's Price Target to $30 From $28, Keeps Outperform Rating MT
Morgan Stanley Trims Price Target on 2seventy bio to $28 From $29, Maintains Overweight Rating MT
Goldman Sachs Lifts Price Target on 2seventy bio to $28 From $25, Maintains Buy Rating MT
SVB Securities Adjusts Price Target on 2seventy bio to $34 From $41, Maintains Outperform Rating MT
SVB Securities Adjusts Price Target on 2seventy bio to $41 From $42, Maintains Outperform Rating MT
Morgan Stanley Adjusts Price Target on 2seventy bio to $29 From $27, Maintains Overweight Rating MT
Guggenheim Starts 2seventy bio at Buy With $30 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
5.35 USD
Average target price
10.5 USD
Spread / Average Target
+96.26%
High Price Target
25 USD
Spread / Highest target
+367.29%
Low Price Target
5 USD
Spread / Lowest Target
-6.54%

Consensus detail

Consensus revision (last 18 months)

Analysts covering 2seventy bio, Inc.

TD Cowen
Leerink Partners
Wedbush
Citigroup
Goldman Sachs
Guggenheim
Morgan Stanley
SVB Securities LLC
Canaccord Genuity
SVB Leerink
Cowen
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings